This document is a translation of the original Japanese document for reference purposes only. In the event of any discrepancy between this document and the Japanese original, the original shall prevail.



June 3, 2025

Company name: Kaneka Corporation Representative: Kazuhiko Fujii, President,

Representative Director

Listing: Prime Market, Tokyo Stock Exchange

Securities code: 4118


Inquiries: Atsuya Inoguchi, Head of Investors

Relations Department (Tel 03 - 5574 - 8090)


### [Updated] Regarding the Management Plan "Three-Year Initiatives 2025"

We hereby announce that we have formulated our new Management Plan "Three-Year Initiatives 2025" (FY2025–FY2027; April 2025 – March 2028), with fiscal year ending March 2026 as its initial year.





# Plan: The Three-Year Initiatives 2025



Section 01

# **Purpose Management**



Purpose Management (Aiming for the goal of making the world healthy)

# Life Focus Management Wellness first Human-Driven Management

Promoting R2B+P\*

Practicing
"Think Global,
Act Local"

Realizing
Human Driven
Company



The Dreamology Company

- Make your dreams come true - Kaneka

We never stay,
Even for a moment

The World is eagerly awaiting you more than ever before




The Kaneka brand is a sign of trust.

I want to be of help to you!




To be a "Change creator," not a "Change thinker"


Traditions become traditions through repeated change



# Everything starts with curiosity and courage

Work and life are about creating your own story





Section 02

# **Core Philosophy**

# **■ Core Philosophy of Management**




Build a dynamic network organization that integrates key strategic domains to drive portfolio transformation



# ■ R2B+P Strategy | Priority Domain



## Tackling the three crises with a focus on Life Science




# ■ Key Themes of R2B+P Strategies: Green Planet



# Latest developments toward full-scale social implementation

- Significant growth expected in adoption by major brand holders.
- Rapid increase in demand for our products due to competitor withdrawals.
- Transition to mass production
- FY2025: Expecting to start full-scale operations at the 15,000-ton demonstration plant.
- FY2026: Planning to move into full production in response to growing adoption by major brand holders worldwide.









### Efforts to increase production capacity

- Accelerating R&D on productivity-enhancing technologies.
- Conducting proprietary R&D on crystallization acceleration technologies to boost molding productivity.



# Green Planet production using CO<sub>2</sub> as a direct feedstock

- Aiming to launch a demonstration plant in FY2030.
- Planning to introduce bench-scale equipment in FY2025 to promote the development of microorganisms with improved CO<sub>2</sub> fixation capabilities.



# Key Themes of R2B+P Strategies: Health Care Field




### Medical

- Expansion of medical device business domain
- → Have earned strong market reputation for mainstay products such as Rheocarna<sup>™</sup> and scoring balloon catheters.
- Broadening portfolio of neurovascular and cardiovascular catheters and expanding into electrophysiology devices.



Coronary treatment device Scoring balloon catheter



Coronary treatment device JMDT's biodegradable stent



Cerebral aneurysm treatment device ESM's *Nautilus* 

### Medical

- Promotion of social implementation of regenerative medicine and cell therapy
- Applying amnion-derived mesenchymal stem cells in clinical trials.
- Expanding target indications and establishing manufacturing system.
- Advancing social implementation of Japan's first fully domestically developed allogeneic MSC-based product.



### Pharma

- Development of biopharmaceutical business
  - Relocating the research base to Europe.
  - Strengthening development of plasmid, protein, and mRNA products.
  - Expanding modalities by introducing animal cell technology.



# ■ Key Themes of R2B+P Strategies: Solar Cell Development



### Expansion of applications

- Expanding applications, including building-integrated photovoltaics (BIPV) and automotive.
- Pursuing improved quality and cost efficiency through innovative technologies aimed at Field Operation Zero (FOZ) and quality management driven by digital transformation (DX).




Tokyo Metropolitan Government's "Model project to visualize renewable energy usage at Tokyo Metropolitan Government-owned facilities (BIPV systems)"



Adopted for Toyota Prius PHEV

### Development of perovskite solar cell technology

- Developing technologies to overcome durability and weather resistance challenges of perovskite materials.
- Developing high-performance, high-reliability tandem-type solar cells and modules by integrating our proprietary heterojunction crystalline silicon technology.
- Achieving cell conversion efficiency of 32.6% with a perovskite/heterojunction crystalline silicon tandem cell (as measured on 1 cm² area by ESTI).
- Developing roof tile-integrated and 3D curved automotive modules.




Perovskite/crystalline silicon tandem roof tile-integrated solar module

# **■** R2B+P Strategy | Strategic Priority Areas



### Concentrate 85% of R2B spending in FY2025 on strategic priority areas







Optical film etc.




**OLED** 


Information interfaces,
Al semiconductors,
Mobility, MS

# **■** R2B+P Strategy Input / Output



- Promoting Research to Business (R2B) initiatives
- Driving portfolio transformation by focusing on R2B investments on priority areas





# I Human Resource Strategy



Our philosophy since our founding

# **Human Driven Company**

A lean, high-quality team and merit-based appraisal

### **Promotion of Diversity**

### **Human Resource Development**

Development of human resources and leaders centered on Kaneka 1-on-1

**Promotion of Wellness** 

By going beyond attributes and tapping into diversity, we bring forth new ideas. In this way, we aim to continue delivering unique Kaneka value that amazes the world.


Since 2018, we have been carrying out Kaneka 1-on-1, a system that aims to drive company growth through personal growth by "lighting a fire in people's hearts."


We are working to improve the wellness of each employee and of our organization. At the heart of this are the ties between our employees.


# I Human Resource Strategy



- Promotion of Diversity
   Diverse individuality delivers unique Kaneka Value
- Promoting women's participation centered on the 1-on-1 Program, increasing the ratios of female executives and female new graduate hires in sales and administrative roles
- Promoting male employees' parental leave and providing seminars for managerial staff







# I Global Strategy



### **Basic Policy**

- Developing global talents who can overcome cultural differences
- Seeking global management resources through M&A / Open Innovation
- Production / Sales systems with deep local roots

### **The Best Glocal Kaneka Ways**

Formulation an overall optimal strategy on a core global centers

X Local adaptability to optimize local resources

### Europe

Expanding business capacity in the environmental and energy, healthcare fields

Asia

Market-out type of business development

### **Americas**

Transforming business model through the adoption of cutting-edge technologies

Japan


Planning and implementing global strategies as a central function

<Enhancing functions of the regional headquarters>

- Thoroughly pursuing growth opportunities by capturing the dynamics of the market
- Envisioning an inspiring and ambitious operational concept that ensures our enduring presence and prominence on the global stage

# **■ Global Strategy** | Pursuing growth drivers in the global market






©2025 Kaneka Group All rights reserved.

# I Manufacturing Strategy: Carbon Neutrality






# ■ Manufacturing Strategy : Digital Transformation



### Creating new value through digital optimization across the entire supply chain







# Plan: The Three-Year Initiatives 2025

## **■** Review of FY2024 the first year of "The Three-Year Initiative 2024"



Net sales : Exceeded ¥800.0 billion, the highest ever.

Operating income

: Achieved the upwardly revised forecast of ¥40.0 billion.

⇒ Sustained strong momentum throughout the year with a profit level of ¥10.0 billion/Q from

2H\* onward.

Return on capital : ROE improved to 5.5%

(100 million yen)		FY2023 Result	FY2024 Plan (Announced in February 2025)	FY2024 Result	Achievement rate (vs. plan)
	Net sales	7,623	8,000	8,072	100.9%
Drofitability	Operating income	326	400	401	100.1%
Profitability	Operating income rate	4.3%	5.0%	5.0%	100.0%
	Net income	232	250	253	101.2%
Return on	ROE	5.3%	5.4%	5.5%	101.9%
capital	ROIC	4.4%	5.1%	5.1%	100.0%

### Kaneka

### **Review of Segment Results (Year-on-Year Comparison)**

- Material : Strong competitiveness shown by MOD, Price revision (sales volume↑,selling price↑)
- QOL : Robust sales of E&I (smartphone and large TVs)(sales volume↑)
- Health Care : Significant sales expansion of new products in Medical (sales volume↑),
  - Prolonged adjustment in CDMO market in Pharma (sales volume)
- Nutrition : Sales expansion of the active form of coenzyme Q10 in Supplement (sales volume<sup>1</sup>)

Profit margin increased (selling price↑)

Achieved sales and profit growth across all segments, as well as the forecasts announced in February 2025

### **Net Sales**

### **Operating Income**

(100 million yen)	FY2023 Result	FY2024 Plan (Announced in February 2025)	FY2024 Result	FY2023 Result	FY2024 Plan (Announced in February 2025)	FY2024 Result
Material	3,229	3,400	3,429	275	305	310
<b>Quality of Life</b>	1,762	1,850	1,910	154	198	200
<b>Health Care</b>	749	790	773	129	144	134
Nutrition	1,872	1,950	1,950	121	138	131
Others	12	10	11	7	4	5
Adjustment	-	-	-	▲360	▲389	▲379
Total	7,623	8,000	8,072	326	400	401





### Initiatives 2025 – How performance targets are defined

- Amid increasing global economic uncertainties, we refined "Plan: Three-Year Initiatives 2024", by re-evaluating the potential impacts of sluggish economy and geopolitical risks.
- Prioritizing achieving profit levels that meet market expectations.

Achieving steady profit growth by accelerating the shift toward Leading-edge businesses and high value-added products

(100 million yen)		FY2024 Result	FY2025 Plan	FY2027 Plan
Profitability	Net sales	8,072	8,200	9,200
	Operating income	401	420	660
	Operating income rate	5.0%	<b>5.1</b> %	<b>7.2</b> %
	Net income	253	330	440
Return on capital	ROE	5.5%	7.2%	10.0%
	ROIC	5.1%	<b>5.2</b> %	8.0%

Exchange rate: ¥145/\$, ¥155/€/ Domestic naphtha:¥70,000/KL

### **■ Plan: The Three-Year Initiative 2025** Performance Targets by segment



Material : Profit growth through application and market expansion, and capacity increase in Asia in MS.

QOL : Sales expansion driven by the launch of new products suited to market growth in ICT sector in E&I.

Health Care : Accelerating global expansion and expanding businesses through the launch of new products, M&A, etc. in Medical and Pharma.

Nutrition : Strengthening Business to Consumer Business in Foods. Expanding sales in the probiotic business in Supplement.

	Net Sales				
(100 million yen)	FY2024 Result	FY2025 Plan	FY2027 Plan		
Material	3,429	3,370	3,700		
Quality of Life	1,910	1,960	2,290		
<b>Health Care</b>	773	910	1,430		
Nutrition	1,950	1,950	1,770		
Others	11	10	10		
Adjustment	-	-	-		
Total	8,072	8,200	9,200		

(100 million yen)	FY2024 Result	FY2025 Plan	FY2027 Plan	
Material	310	310	365	
Quality of Life	200	210	270	
<b>Health Care</b>	134	171	290	
Nutrition	131	137	150	
Others	5	5	5	
Adjustment	▲379	<b>▲</b> 413	<b>▲</b> 420	
Total	401	420	660	

**Operating Income** 

### **I** Portfolio Transformation



- Actively allocating management resources to the Leading-edge businesses to drive continuous portfolio transformation.
- Aiming to increase the share of Leading-edge businesses in operating income to over 50% in FY2025 and to 60% in FY2027.

### Leading-edge businesses

Achieve dramatic growth by strategic investment in human resources, goods, and capital

### Performance Polymers(MS)

E & I Technology

PV & Energy management

Medical

Pharma

**Supplemental Nutrition** 

### [Key initiatives]

MS: Business expansion by capturing demand for environmentally friendly solutions and simplified construction method.

E&I: Market growth in ICT sector and launching new products.

Medical: Expanding business through expansion of new products and sales areas, and M&A.

Pharma: New product development and business expansion through M&A.

### **Foundation businesses**

Steadily strengthen capabilities to earn cash by reinforcement of business foundation


Vinyls and Chlor-Alkali

Performance Polymers(MOD)

Foam & Residential Techs

Performance Fibers

Foods & Agris



# **I** Portfolio Change Drivers



### **Growth drivers leading Kaneka's portfolio transformation**

### New high-value-added products

MOD

: Non-PVC resin modifier, MX

Foam

: New method foaming products

Fibers

: New functional performance fibers

Foods


: New products for consumers such as dairy products, etc.



**Leading-edge businesses** 

New high-value-added products

Portfolio change drivers



# I Key Strategies by Segment (Material Solutions Unit)



### Vinyls and Chlor-Alkali SV

### Scaling up businesses rooted in Asia as "Kaneka in Asia"

### Building a hybrid model with Japan and Asia operating in parallel

- Expanding polymer business in Asia (ASEAN and India).
- Driving global deployment leveraging specialty PVC.

### Performance Polymers (MS) SV

Advancing unique polymerization and modification technologies to create new markets

# Driving rapid business growth by offering solutions addressing environmental issues and other social challenges


- Expanding market share by developing technologies competitive with other materials (urethane, silicone, etc.).
- Capturing emerging demand for more energy-efficient buildings and more simplified construction.
- Tapping into markets in ASEAN and India and strengthening capacity in Asia.

### Performance Polymers (MOD) SV

Driving the R2B business by modifying matrix resins to delivery surprising transformation

# Expanding applications through deepening core-shell technology and regionally rooted development activities

- Expanding new products for non-PVC.
- Increasing epoxy masterbatch sales (for composite materials etc.).
- Accelerating deployment of acrylic films for automotive applications.



# I Key Strategies by Segment (Quality of Life Solutions Unit)



### Foam & Residential Techs SV

# Transforming portfolio by advancing foaming technologies to anticipate shifts in industrial structures

### Strengthening global deployment and launching new products

- > Expanding sales of foamed polyolefins in ASEAN in Indian market.
- Developing markets for new products such as ultra-high insulation grades and Green Planet foams.

### E&I Technology SV

# Establishing a strong presence as a pioneer in untapped growth areas of the evolving electronics industry

# Advancing applications for information interfaces and broadening new growth fields

- Developing phase-difference grades to meet the needs for higherdefinition TVs.
- Capturing demand for high-speed ICT technologies (AI, autonomous driving).

### **PV & Energy management SV**

# Delivering unique and attractive solutions based on proprietary solar cell technology development

# Developing and delivering products aligned with growing demand toward carbon-neutral society


- Accelerating application to building exteriors and openings.
- > Expanding sales in renovation market.
- ➤ Developing flexible solar cells and establishing mass production technology.

### **Performance Fibers SV**

# Advancing manufacturing innovation and developing unique high-performance fiber solutions

# Strengthening base product portfolio for hair and flame-retardant materials and develop new applications with new products

- > Strengthening local marketing and expanding hair-related use cases across multiple African countries.
- > Strengthening flame-retardant materials segment by launching ecofriendly grades.
- Expanding business into environmental sector by developing innovative technologies.



# I Key Strategies by Segment (Health Care Solutions Unit)



### **Medical SV**

### Accelerating global expansion of world-leading medical technologies

# Driving growth by the expansion of new technologies product lineup and advancing globalization


- Expanding business areas through M&A and other measures and bringing new technologies (products) to market.
- Opening a catheter plant at Tomatoh (Hokkaido) Plant (accelerating overseas expansion).
- Strengthening R&D in the U.S.
- Expanding business domains by entering new areas such as regenerative cell medicine, and women's healthcare.

### Pharma & Supplemental Nutrition SV (Pharma)

Creating scalable niche and core businesses in the expanding pharmaceutical market by linking open innovation with Kaneka's unique capabilities

### Enhancing differentiated technologies and market development capabilities

- Focusing on U.S. market development for small molecule pharmaceuticals.
- Enhancing cost competitiveness and expanding into new business areas through M&A (biopharmaceuticals).
- Expanding sales through enhanced market development in Asia and increasing production capacity (biochromatography).



# I Key Strategies by Segment (Nutrition Solutions Unit)



### **Pharma & Supplemental Nutrition SV (Supplement)**

Building a global brand with active form of coenzyme Q10 as its core and honing our technology to establish as a leading company in the new probiotics business

### Business expansion by positioning the U.S. as the most critical market


- ➤ Focusing on boosting sales of active form of coenzyme Q10 in the U.S. market (tap demand in the healthy aging field).
- Strengthening sales of probiotics products with a focus on women, infants, and intestinal regulation.

### Foods & Agris SV

Shifting to a new strategy that anticipates diverse food cultures and delivers value-added food products to consumers.

### Increasing profitability by transforming portfolio

- ➤ Leveraging our fully integrated operations starting from dairy farming to create and expand organic dairy market.
- Scaling up the Healthy Foods business by expanding product portfolio.
- > Capturing the Asian market with processed oils and spices.



### I Investment Plan



Renewing product portfolio by introducing new products in the Foundation businesses.

©2025 Kaneka Group All rights reserved.

• Creating a positive investment cycle by scaling up the Leading-edge businesses.

### < Plan for capital investment (FY2025 – FY2027) >

Total amount of investment (including M&A)








### I Investment Plan





©2025 Kaneka Group All rights reserved.

### **■ Cash Allocation** FY2025-FY2027



### **Cash inflows**

### **Cash outflows**

# **Operating Cash Flow**

Approx. ¥260.0 billion

 Profit growth driven by business portfolio transformation

Reduction of Cross-shareholdings

Approx. ¥25.0 billion

Accelerating the pace of reduction

**Interest-bearing Debt** 

 Expansion of ESG finance (Green bond/ Social bond)

# Investing Cash Flow

Approx. ¥240.0 billion

- Investment in enhancing capabilities
- Investment in strengthening the foundation

# Shareholder Returns

Approx. ¥60.0 billion

- Stable dividends (progressive dividend policy)
- Continued flexible repurchase of treasury shares

M&A

 Creating new synergies through active M&A

31





# Improvement of Return on Capital and Shareholder Returns

# I For Improvement of Return on Capital



Major initiatives

### KPIs related return on capital

### 1. Promoting growth strategy

### **Accelerating business portfolio transformation**

- ⇒ Shift to Leading-edge businesses and improvement of profitability in the Foundation businesses.
- ⇒ Realizing returns from major investments while expanding profits through aggressive growth investments.

### 2. Promoting capital / financial strategies Improving capital efficiency promptly

- ⇒ Further enhancement of shareholder returns. (through stable dividends, flexible repurchase of treasury shares, reduction of cross-shareholdings)
- ⇒ Active cash allocation toward growth investments.





Improve KPIs to return on capital

3

# **■ Trends of Key Indicators**







### Aim for over 8.0% in FY2026

Aiming to continuously improve return on capital and enhance shareholder value.

### Aim for over 8.0% in FY2027

Striving to exceed the cost of capital at an early stage, with a strong focus on both profitability and return on capital in management.

# I Policy of Shareholder Returns



Enhancing shareholder returns by using business profits and capital gains generated by reducing cross-shareholdings.

**Dividends** 

**Implementing progressive dividends** and ensuring stable dividends over medium to long term (FY2025 - FY2027)

Repurchase of treasury shares


Continuous flexible repurchase of treasury shares

FY2024 Result ¥5.0 billion FY2025 Plan ¥12.0 billion

Dividend payout ratio

Target of consolidated dividend payout ratio: over 30%


(Flexibly consider total return ratio of 40% or more as benchmark)




# Reduction of Cross-Shareholdings



- Aiming for a net asset ratio of 10% or less by the end of FY2025.
- Steadily reducing cross-shareholdings, with a goal of halving their value by the end of FY2027.
- Funds generated through these reduction will be allocated to growth investments and shareholder returns, including dividends and repurchase of treasury shares.







# **■** Repurchase of Treasury Shares



- Consistently repurchased treasury shares since FY2022.
- Decided to repurchase and cancel up to 3 million shares (with an upper limit of ¥12.0 billion), as announced on May 14, 2025.
- Continue flexible and timely share repurchases policy to promote optimal capital structure and enhance shareholder returns.





# ■ Appendix: The List of Kaneka Business Unit Abbreviations Kaneka



Material SU	Material Solutions Unit
Vinyls	Vinyls & Chlor-Alkali Solutions Vehicle
MOD	Performance Polymers (MOD) Solutions Vehicle
MS	Performance Polymers (MS) Solutions Vehicle









### Disclaimer:

This presentation material is provided solely for the purpose of enhancing your understanding of Kaneka and is not intended as a solicitation or recommendation for any investment or other action.

The information contained herein is based on data currently available to the company and on forecasts and other assumptions made at the time of preparation. These statements are not guarantees of future performance and involve certain risks and uncertainties. Accordingly, please be advised that actual results may differ materially from the outlooks or forecasts described in this presentation material.

This English translation is provided for reference purposes only. In the event of any discrepancies between the original Japanese version and this English translation, the original Japanese version shall prevail.